FDA Approves Novartis Drug Promacta® for First-line SAA |Breakthrough Therapy Designation
FDA Approves Novartis Drug Promacta® for First-line SAA |Breakthrough Therapy Designation By: Novartis News Basel, November 16, 2018 – Novartis announced today that the US Food and Drug Administration (FDA) has expanded the label for Promacta®(eltrombopag) to include first-line treatment for adults and pediatric patients two years and older with SAA in [..]